Welcome to CDC stacks |
Stacks Logo
Advanced Search
Select up to three search categories and corresponding keywords using the fields to the right. Refer to the Help section for more detailed instructions.
 
 
Help
Clear All Simple Search
Advanced Search
Serogroup A Neisseria meningitidis with Reduced Susceptibility to Ciprofloxacin
  • Published Date:
    Oct 2008
  • Source:
    Emerg Infect Dis. 14(10):1667-1669
  • Language:
    English
Filetype[PDF-127.61 KB]


No Related Documents.
You May Also Like:
  1. Population-Based Surveillance of Neisseria meningitidis Antimicrobial Resistance in the United States
    Personal Author:
    Harcourt, Brian H.; Anderson, Raydel D.; Wu, Henry M.; Cohn, Amanda C.; MacNeil, Jessica R.; Taylor, Thomas H.; Wang, Xin; Clark, Thomas A.; Messonnier, Nancy E.; Mayer, Leonard W.;
    Published Date:
    Aug 13 2015
    Source:
    Open Forum Infect Dis. 2015; 2(3).
    Description:
    Background.  Antimicrobial treatment and chemoprophylaxis of patients and their close contacts is critical to reduce the morbidity and mortality and prevent secondary cases of meningococcal disease. Through the 1990's, the prevalence of antimicrobi...
    File Type:
    Filetype[PDF - 128.34 KB]
  2. Ciprofloxacin Resistance in Neisseria meningitidis, France
    Personal Author:
    Skoczynska, Anna; Alonso, Jean-Michel; Taha, Muhamed-Kheir;
    Published Date:
    Aug 2008
    Source:
    Emerg Infect Dis. 14(8):1322-1323.
    File Type:
    Filetype[PDF - 117.01 KB]
  3. Mass Chemoprophylaxis for Control of Outbreaks of Meningococcal Disease
    Personal Author:
    McNamara, Lucy A.; MacNeil, Jessica R.; Cohn, Amanda C.; Stephens, David S.;
    Published Date:
    May 29 2018
    Source:
    Lancet Infect Dis. 18(9):e272-e281
    Description:
    Although vaccination is the main strategy used to control meningococcal disease outbreaks, mass chemoprophylaxis has also been used as an immediate response to outbreaks, either to supplement vaccination or when vaccination is not possible. However, ...
    File Type:
    Filetype[PDF - 238.93 KB]
  4. Imported Ciprofloxacin-Resistant Neisseria meningitidis
    Personal Author:
    Lapadula, Giuseppe; Viganò, Franco; Fortuna, Paolo; Dolara, Alberto; Bramati, Simone; Soria, Alessandro; Foresti, Sergio; Gori, Andrea;
    Published Date:
    Nov 2009
    Source:
    Emerg Infect Dis. 15(11):1852-1854.
    File Type:
    Filetype[PDF - 208.61 KB]
  5. Detection of Ciprofloxacin-Resistant, β-Lactamase–Producing Neisseria meningitidis Serogroup Y Isolates — United States, 2019–2020
    Personal Author:
    McNamara, Lucy A.; Potts, Caelin; Blain, Amy E.; Retchless, Adam C.; Reese, Natashia; Swint, Stephanie; Lonsway, David; Karlsson, Maria; Lunquest, Kristy; Sweitzer, John J.; Wang, Xin; Hariri, Susan; Fox, LeAnne M.; Dhungana, Nirmala; Gabrio-Brannon, Ryan; Kyle, Jennifer; Martin, Brittany; Barnes, Meghan; Moore, Ashley; Hannagan, Susan; Keating, Page; Li, Sandy; Albertson, Justin; Fleming, Wayne; Lurie, Perrianne; Russell, Christina; Reid, Kara; Sanders, Kelsey; DeBolt, Chas; Graff, Nicholas; Lam, Esther; Hanisch, Benjamin; Taormina, Gillian;
    Corporate Authors:
    Antimicrobial-Resistant Neisseria meningitidis Team. National Center for Immunization and Respiratory Diseases (U.S.). Division of Bacterial Diseases.. National Center for Emerging and Zoonotic Infectious Diseases (U.S.). Division of Healthcare Quality Promotion.. Maryland. Department of Health..
    Published Date:
    June 19 2020
    Source:
    MMWR Morb Mortal Wkly Rep. 69(24):735-739
    Description:
    Meningococcal disease is a sudden-onset, life-threatening illness caused by the bacterium Neisseria meningitidis. Prompt empiric antibiotic treatment can reduce morbidity and mortality among patients, and antibiotic prophylaxis can prevent secondary ...
    File Type:
    Filetype[PDF - 176.57 KB]